Bio-Rad Laboratories, Inc. entered into a Credit Agreement dated as of February 13, 2024 (the Revolving Credit Agreement), by and among the Company, Bio-Rad Europe GmbH, Bio-Rad IHC Europe GmbH and Bio-Rad Laboratories (Singapore) Pte Ltd. (collectively, the Borrowers), the lenders referred to therein, and Wells Fargo Bank, National Association, as agent. The Revolving Credit Agreement replaced the Company?s previous Credit Agreement, dated as of April 15, 2019 (Previous Revolving Credit Agreement), by and among the Company, the lenders referred to therein, JPMorgan Chase Bank, N.A., as administrative agent, Bank of America, N.A., HSBC Bank USA, National Association, and MUFG Bank Ltd. as co-syndication agents, and Citibank, N.A. and Wells Fargo Bank, National Association as co-documentation agents, as amended. The Company repaid in full all outstanding obligations under the Previous Revolving Credit Agreement on February 14, 2024 and terminated all commitments thereunder.

No penalties were due in connection with such repayments. Borrowings under the Revolving Credit Agreement are permitted up to a maximum amount of $200,000,000 on a revolving basis, including up to $25,000,000 of letters of credit. Borrowings of revolving loans may be made, at the Borrowers?

election, in U.S. dollars, Euros, Swiss Francs, Japanese Yen, Pounds Sterling and Singapore Dollars, and letters of credit may be issued, at the Borrowers? election, in U.S. dollars or Euros. Borrowings under the Revolving Credit Agreement will be used to make acquisitions, for working capital and for other general corporate purposes.

The Revolving Credit Agreement matures on February 13, 2029, which date may be extended up to three times upon the mutual agreement of the Borrowers and the relevant lenders, pursuant to procedures set forth in the Revolving Credit Agreement. The Borrowers must repay in full all outstanding obligations under the Revolving Credit Agreement on the maturity date of such agreement. The Revolving Credit Agreement contains covenants and provisions that constrain certain actions of the Borrowers and their subsidiaries, including, among others, the following customary covenants and provisions: limiting the ability to incur debt (subject to certain exceptions); limiting the ability to sell assets (subject to certain exceptions); limiting the ability to create or incur specified liens on its property (subject to certain exceptions); and prohibiting consolidations, mergers and asset transfers (subject to certain exceptions).

Under the Revolving Credit Agreement, the Company also must maintain a consolidated leverage ratio not greater than 3.50 to 1.00 for the most-recently ended four fiscal quarter period, which shall be tested quarterly commencing with the fiscal quarter ending December 31, 2023.